This category page covers biotechnology and pharmaceutical companies developing neuroimmune resolution therapies, specialized pro-resolving mediator (SPM) approaches, and pro-resolving cytokine modulators for Alzheimer's disease. Chronic neuroinflammation is a core pathological feature of AD, characterized by ongoing activation of microglia and astrocytes. SPMs — including resolvins, protectins, maresins, and lipoxins — represent a novel therapeutic approach that actively promotes resolution of inflammation rather than simply suppressing it.
Companies targeting this pathway aim to shift the brain's immune state from chronic inflammation to active resolution, protecting neurons, preserving synaptic function, and potentially slowing disease progression.
Focus: SPM receptor agonists for neuroinflammation resolution
Mechanism: Develops synthetic resolvins and protectins that activate G-protein coupled receptors (ALX/FPR2, GPR32) to trigger active inflammation resolution
Indication: Alzheimer's disease, other neurodegenerative conditions
Stage: Research/lead optimization
Notes: Pioneer in SPM receptor pharmacology; platform spans multiple SPM analogs and receptor targets
Focus: Pro-resolving cytokine and complement modulation
Lead Candidate: XPro1595 (DN-TNF inhibitor)
Mechanism: Selective inhibition of soluble TNF (not membrane TNF) to reduce neuroinflammation while preserving immune surveillance; promotes pro-resolving state
Indication: Alzheimer's disease
Stage: Phase 2
Notes: Phase 1 data showed reduction in neuroinflammatory biomarkers. Novel approach targeting chronic inflammation without suppressing normal immune function
Clinical Trials: Phase 2 in AD patients with elevated inflammatory markers
Key Targets: Soluble TNF, neuroinflammation, cognitive function
Nodthera
Focus: NLRP3 inflammasome inhibitors
Lead Candidate: NT-0796
Mechanism: Oral NLRP3 inhibitor blocking upstream inflammasome activation; reduces IL-1beta and IL-18 production
SPMs act through G-protein coupled receptors (ALX/FPR2, GPR32, GPR18) to:
Block neutrophil infiltration
Promote macrophage/microglial phagocytosis
Reduce cytokine production
Enhance clearance of cellular debris
Support tissue repair
TREM2 plays a critical role in microglial response to amyloid; genetic variants affecting TREM2 function increase AD risk, validating this as a therapeutic target[@trem2_pathway].
References
[Neuroinflammation in AD (Nature Reviews Neuroscience, 2023)](https://www.nature.com/articles/s41582-023-00789-0)
[SPMs in neurodegenerative diseases (Brain Behavior and Immunity, 2024)](https://www.sciencedirect.com/journal/brain-behavior-and-immunity)
[TREM2 and neuroimmune signaling (Neuron, 2023)](https://www.cell.com/neuron)
[Targeting IL-1 in AD (Alzheimer's & Dementia, 2022)](https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.12594)
See Also
[Neuroinflammation Overview](/mechanisms/neuroinflammation-mechanism) — Chronic brain inflammation in AD/PD
[TREM2 Protein](/proteins/trem2-protein) — Microglial receptor for amyloid clearance
[NLRP3 Inflammasome](/mechanisms/nlrp3-inflammasome-pathway) — Key driver of neuroinflammation
[Microglia in AD](/cell-types/microglia) — Brain immune cells and neuroinflammation
[Cytokines in Neurodegeneration](/mechanisms/cytokine-signaling-pathways) — IL-1, TNF, IL-6 signaling